Chemistry:Quabodepistat
From HandWiki
Quabodepistat is an investigational new drug of the fluoroquinolone antibiotic class that is being evaluated by Otsuka Pharmaceutical for the treatment of tuberculosis. It is a DprE1 enzyme inhibitor.[1][2][3] DprE1 is required for the synthesis of arabinogalactan, a component of the tuberculosis cell wall, so inhibiting this enzyme disrupts cell wall construction and therefore kills the bacteria.[4]
Clinical trials
Quabodepistat is currently in phase 3 clinical trials for tuberculosis.[5]
References
- ↑ "Quabodepistat - Otsuka Pharmaceutical; Otsuka Pharmaceutical Development & Commercialization". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800051210.
- ↑ "OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor". Antimicrobial Agents and Chemotherapy 64 (6). May 2020. doi:10.1128/AAC.02020-19. PMID 32229496.
- ↑ "Targeting the Heart of Mycobacterium: Advances in Anti-Tubercular Agents Disrupting Cell Wall Biosynthesis". Pharmaceuticals (Basel, Switzerland) 18 (1): 70. January 2025. doi:10.3390/ph18010070. PMID 39861133.
- ↑ "Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy". Trials 25 (1). January 2024. doi:10.1186/s13063-024-07912-5. PMID 38243296.
- ↑ Clinical trial number NCT07209761 for "Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB" at ClinicalTrials.gov
 |  |
